Private biotech company Dren Bio has entered into a strategic collaboration with French drugmaker Sanofi to develop therapies ...
Dren Bio retains the option to co-fund future development in exchange for U.S. co-promotion rights with Sanofi, a 50/50 share ...
Sanofi bought Dren’s DR-0201 program earlier this year for $600 million upfront and is running two Phase I trials in ...
Pharmaceutical Technology on MSN
Sanofi signs pair of billion-dollar biotech deals to bolster pipeline
"Sanofi signs pair of billion-dollar biotech deals to bolster pipeline" was originally created and published by ...
As 2025 closes out, a pair of autoimmune biotechs have eked out separate deals with Big Pharma before year-end, each with a sizable potential payout down the line. | Seattle’s Adaptive Biotechnologies ...
ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and ...
Dren Bio, a privately held, US clinical-stage biotechnology company developing first-in-class myeloid cell engager ...
South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi to ...
Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front Paris, ...
1d
Dren Bio to collaborate with Sanofi to develop autoimmune disease therapies for up to $1.7 billion
Dren Bio, a private biotech company, said on Monday it has entered into a strategic collaboration with Sanofi to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results